KLRA
Kailera Therapeutics, Inc. · Healthcare
Insiders bought $326.8M of Kailera Therapeutics, Inc. in the last 12 months
5 insiders bought on 1 day.
KLRA over the last year
Largest buyers, last 12 months
KLRA after insider buys
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
5 insider filings since 2026, newest first
Rtw Investments, LP · 10% owner
Bain Capital Investors LLC · 10% owner
Adam Koppel · Director and 10% owner
Bain Capital Life Sciences Investors, LLC · 10% owner
Andrew T. Kaplan · Director and 10% owner
About Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.